文献速递肿瘤 PET/CT核素与放射性配体治疗

SCARLET试验:生长抑素受体显像用于复发难治性多发性骨髓瘤患者潜在放射性诊疗应用的前瞻性II期研究

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-28

这项前瞻性II期研究纳入17例三类药物暴露的复发难治性多发性骨髓瘤患者,均在[18F]F-FDG PET/CT显示病灶后4周内行[68Ga]Ga-DOTATATE PET/CT。所有患者均有[68Ga]Ga-DOTATATE摄取,15例见局灶性摄取,10例(60%)符合肽受体放射性核素治疗(PRRT)入选标准,提示PRRT在部分患者中的潜在新适应证。

要点

  • 17例复发难治性多发性骨髓瘤患者中,15例在[68Ga]Ga-DOTATATE PET/CT上见局灶性摄取。
  • 10/17例(60%)符合PRRT入选标准:无FDG局灶无DOTATATE对应摄取、DOTATATE局灶≥3个、无弥漫骨髓摄取。
  • 联合FDG与DOTATATE PET/CT可将患者分为4类,其中第1、2类且DOTATATE局灶≥3个者视为PRRT合格。

核心结论

  • 在[18F]F-FDG PET/CT显示 avid 病灶的重度经治复发难治性多发性骨髓瘤患者中,[68Ga]Ga-DOTATATE PET/CT识别出60%的患者为PRRT合格候选者,提示PRRT在部分患者中的潜在新适应证。

研究设计与样本

  • 前瞻性II期研究,纳入17例三类药物暴露的复发难治性多发性骨髓瘤患者,均经[18F]F-FDG PET/CT显示 avid 病灶。
  • 患者在标准流程[18F]F-FDG PET/CT后4周内行[68Ga]Ga-DOTATATE PET/CT,局灶性病灶定义为摄取高于股骨骨髓本底摄取。
  • PRRT合格标准:无[18F]F-FDG avid 局灶而无对应[68Ga]Ga-DOTATATE摄取、[68Ga]Ga-DOTATATE局灶性病灶≥3个、[68Ga]Ga-DOTATATE PET/CT无弥漫骨髓摄取。

主要发现

  • 所有患者[18F]F-FDG PET/CT均有可测量病灶,所有患者均见[68Ga]Ga-DOTATATE摄取,15/17例见局灶性病灶。
  • 联合分析将患者分为4类:两类示踪剂识别相同局灶;所有FDG局灶均有对应DOTATATE摄取并见额外DOTATATE局灶;仅部分FDG局灶见DOTATATE摄取;DOTATATE弥漫骨髓摄取妨碍局灶识别。
  • 第1、2类患者若[68Ga]Ga-DOTATATE PET/CT见≥3个局灶性病灶则视为PRRT合格,最终10/17例(60%)符合PRRT入选标准。

关键数值与推荐

  • PRRT合格标准:无[18F]F-FDG avid 局灶而无对应[68Ga]Ga-DOTATATE摄取、[68Ga]Ga-DOTATATE局灶性病灶≥3个、[68Ga]Ga-DOTATATE PET/CT无弥漫骨髓摄取。
  • 10/17例(60%)符合PRRT入选标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase II study investigates the expression of somatostatin receptors (SSTR) in relapsing and refractory multiple myeloma (rrMM) patients for potential radiotheranostic application. METHODS: Seventeen triple-class exposed rrMM patients who demonstrate [18F]F-FDG avidity were prospectively included. Patients underwent a [68Ga]Ga-DOTATATE PET/CT within 4 weeks after [18F]F-FDG PET/CT, which was performed as part of the standard workup. Focal lesions (FLs) were identified on both scans and were defined as focal uptake higher than the femoral bone marrow background uptake. Peptide Receptor Radionuclide Therapy (PRRT) eligibility was determined based on the following criteria: absence of [18F]F-FDG-avid FLs without corresponding [68Ga]Ga-DOTATATE uptake, identification of ≥ 3 [68Ga]Ga-DOTATATE FLs, and no diffuse bone marrow uptake on [68Ga]Ga-DOTATATE PET/CT. RESULTS: All patients had measurable disease on [18F]F-FDG PET/CT. [68Ga]Ga-DOTATATE uptake was observed in all patients, with FLs identified in 15 of the 17 patients. The combined [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT analyses classified patients into 4 categories: (1) Identical FLs identified by both radiotracers; (2) All [18F]F-FDG FLs showed corresponding [68Ga]Ga-DOTATATE uptake, with additional [68Ga]Ga-DOTATATE FLs; (3) Only some of the [18F]F-FDG FLs showed [68Ga]Ga-DOTATATE uptake; (4) Diffuse bone marrow uptake of [68Ga]Ga-DOTATATE, preventing FLs identification. Patients in categories 1 and 2 were deemed PRRT-eligible if they had ≥ 3 FLs on [68Ga]Ga-DOTATATE PET/CT. Consequently, 10 out of 17 patients (60%) met the PRRT eligibility criteria. CONCLUSION: In heavily pretreated rrMM patients showing avid disease on [18F]F-FDG PET/CT, [68Ga]Ga-DOTATATE PET/CT identified 60% of patients as eligible candidates for PRRT, suggesting a potential new indication for PRRT in selected patients. TRIAL REGISTRATION: NCT04379817, Registered on 4 May 2020, https://clinicaltrials.gov/study/NCT04379817?cond=multiple%20myeloma&term=scarlet&rank=1.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Delbart W, Karfis I, Vercruyssen M, et al. The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40866646. doi:10.1007/s00259-025-07500-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。